CellCentric is a clinical-stage biopharmaceutical company focused on the development of a first-in-class oral p300/CBP inhibitor to treat multiple myeloma and other cancer types
CellCentric is a clinical-stage biopharmaceutical company focused on the development of a first-in-class oral p300/CBP inhibitor to treat multiple myeloma and other cancer types.